Cargando…
Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
Type I interferon is promising in treating different kinds of tumors, but has been limited by its toxicity, lack of tumor targeting, and very short half-life. To target tumors, reduce systemic toxicity, and increase half-life, here we engineer a masked type I IFN-Fc (ProIFN) with its natural recepto...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497482/ https://www.ncbi.nlm.nih.gov/pubmed/34620867 http://dx.doi.org/10.1038/s41467-021-26112-2 |